Predict potential drug induced liver injury (DILI) in vitro using a physiologically relevant 3D human liver model
- Leverage metabolically competent 3D InSight™ Human Liver Microtissues in a standardized 14 day, repeat-dose experimental setup
- Predict hepatotoxicity in an extensively validated 3D model system that achieves > 70% sensitivity and > 90% specificity classifying more than 100 known DILI compounds
- Enhance data quality and predictions with highly standardized, reproducible model
- Receive results within 3-4 weeks following receipt of compounds of interest
Service at a Glance
Our 14 day repeat-dosing protocol
Our organotypic 3D liver model. 3D InSight™ Human Liver Microtissues are composed of pooled multi-donor primary human hepatocytes (PHH) co-cultured with Kupffer cells. They display polarized, cuboidal shaped hepatocytes, integration of CD68+ Kupffer cells, and formation of functional bile canaliculi (BSEP shown), representing intact cholestatic and inflammatory mechanisms of DILI.
Robust, stable CYP profile. 3D InSight™ Human Liver Microtissues are metabolically competent in long-term culture, as demonstrated by active turnover of CYP substrate probes. Composed of pooled hepatocytes from 5 male and 5 female donors, the model more closely approximates the average human metabolic profile.
Reproducible and sensitive. Long-lived Human Liver Microtissues enable 14 day exposure with repeat dosing, improving assay sensitivity. Our highly uniform, standardized model produces reliable IC50 data (Chlorpromazine shown) across microtissue production runs, ensuring reproducibility for longitudinal studies.
ATP assay reproducibility. 3D InSight™ Human Liver Microtissues (MT) were cultured for 14 days (untreated) and intra-tissue ATP content was assessed. In each assay (n = 40) average relative light units (RLU) from triplicates (3 MT) was set to 100%. Relative standard deviation (SD) of the mean of 40 assays is depicted. Average relative SD is 14.6%.